Shanghai, China, 11 May 2025 - MicroPort® Endovastec™ announced that its Talos™ Thoracic Stent Graft System (Talos™) has recently received marketing approval in Brazil and Argentina, marking an important milestone in the company’s global strategy and its commitment to improving patient access to advanced aortic therapies.
Talos™ is a next-generation straight thoracic stent graft system, and the world’s first “breathing” stent graft specifically designed for the treatment of Stanford type B aortic dissection. It can improve the reshaping of the distal true lumen by extending the stent length. Its unique distal honeycomb design (length can be selected from 0 mm to 200 mm) can enlarge the distal true lumen diameter of the thoracic aorta, reduce the possibility of spinal cord ischemia caused by overlying intercostal arteries, and improve the long-term treatment outcomes. With a maximum stent length of 260 mm, Talos™ is designed to optimize aortic remodeling outcomes in complex cases.
Latin America represents a key region in MicroPort® Endovastec™’s global footprint. The company’s aortic product portfolio is already in clinical use across several countries in this region, including Brazil, Argentina, Colombia, and Mexico. The approval of Talos™ in Brazil and Argentina will further reinforce the company’s regional presence and broadens the range of innovative treatment options available to patients with aortic disease.
About MicroPort® Endovastec™
Founded in 2012, MicroPort® Endovastec™ (Shanghai MicroPort Endovascular MedTech Group Co., Ltd.; SSE: 688016), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is a global medical device company focusing on R&D, manufacturing, and commercialization of aortic and peripheral vascular interventional devices. MicroPort® Endovastec™'s product portfolio includes thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, peripheral vascular stents, and drug-coated PTA balloon catheters. MicroPort® Endovastec™ breaks barriers and accelerates innovation to provide trustworthy and universal access to state-of-the-art solutions for prolonging and reshaping all lives, and to build a leading enterprise of emerging technologies in great vessel surgery and peripheral vascular medicine.
More information is available at: www.endovastec.com/en